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CLINICAL INVESTIGATION
Residual renal function in hemodialysis patients may protect
against hyperaluminemia
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Residual renal function in bemodialysis patients may protect against
hyperaluminemia. We investigated 106 home hemodialysis patients
whose mean [±5CM] serum aluminum (Al) concentration was 60.9 4.1
jig/liter. Serum Al concentration was inversely related to daily urine
output (r = —0.52, P < 0.001). Urine volume and measurements of Al
exposure were included in a multivariate analysis of serum Al concen-
tration in the 62 patients whose urine output was greater than 10 mI/day.
The multiple correlation coefficient (r) was 0.70 (P < 0.001) and the
percentage contributions to r2 (indicating the relative importance of
each factor) were: urine output 57%, oral Al intake 36%, total dialysis
hours 7%. The additional contribution from cumulative water Al was
negligible. In a subgroup of 26 patients with a urine output exceeding 10
mi/day, urinary Al excretion averaged 15.4 jig/day, and renal Al
clearance and serum Al concentration were inversely related (r
—0.69, P < 0.001). We conclude that Al-containing phosphate binders
were a more important source of Al than was dialysate in these patients
and that residual renal function can reduce the severity of hyper-
aluminemia in hemodialysis patients.
Aluminum (Al) accumulates in patients undertaking dialysis
in whom it can cause osteomalacia, encephalopathy, and ane-
mia [1—41. The principal sources of this Al are the water used to
prepare dialysate and Al-containing phosphate binders [2, 5].
Because of the wide variation in serum Al concentrations
amongst patients with apparently similar Al exposure, we have
investigated the possibility that the rate of excretion of Al in the
urine of hemodialysis (HD) patients might affect their serum Al
concentrations.
Methods
Patients
One hundred and six home HD patients (80 male aged 24 to 61
yr, 26 female aged 26 to 61 yr) were studied. Sixty—two of these
passed more than 10 ml, and 30 more than 500 ml of urine per
day. Daily urine volumes of less than 10 ml were regarded as
zero. Dialysate was a 34:1 dilution of "Renalyte" HD concen-
trate (Macarthys Laboratories) in softened tap water. Neariy all
the patients had been taking Al hydroxide as Am-Cap (164 mg
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elemental Al per capsule) (Riker), Aludrox gel (22 mg elemental
Al per ml), or Aludrox tablets (134 mg elemental Al per tablet)
(Wyeth). Since May 1983 Al was measured in serum every four
months and in softened water (used to prepare dialysate)
monthly. Between 1979 and May 1983 monitoring was less
frequent. All sample collecting and measuring equipment was
shown to be free of contamination with Al.
Aluminum assay
Equipment. Estimations were performed using a Varian
AA1275 atomic absorption spectrophotometer and GTA95 elec-
trothermal atomizer [61, fitted with an auto-sampler (Varian
Associates). Pyrolytically—coated graphite tubes were used.
Serum. The within batch coefficient of variation (CV) was
10% at 20 jig/liter and 5% at 100 jig/liter. The between batch CV
was 7.5% at 55 jig/liter. The detection limit (Al concentration
giving an absorbance signal equal to twice the standard devia-
tion of the signal from a reagent blank) was 1.8 jig/liter. The
characteristic concentration (amount of Al giving 1% absorp-
tion) was 15 pg.
Urine. Due to widely different matrix effects between sam-
ples, the method of additions was used. The within batch CV
was 7% at 40 jig/liter. The detection limit was 2 jig/liter and the
characteristic concentration 15 pg. All urine assays were run as
a single batch.
Softened water and dialysate. The between batch CV for
softened water was 5% at 20 jig/liter. The detection limit was
0.7 jig/liter and the characteristic concentration was 10 pg. Al in
dialysate was measured against standards made in a I in 35
dilution of "Renalyte" in deionized water. The between batch
CV was 10% at 15 jig/liter. The detection limit was 0.5 jig/liter
and the characteristic concentration was 7 pg. There was no
difference between concentrations of Al in softened water and
dialysate in 80 paired measurements over the range 1 to 26
jig/liter, (r = 0.95, P C 0.001). Therefore the use of soft water
Al measurements to indicate the exposure of patients to Al from
dialysate was valid.
Creatinine clearance. Serum creatinine was assayed using an
autoanalyzer (Technicon SMAC) and urine creatinine with a
Technicon AA2 single channel analyzer [7]. Because the 24-
hour urine collection was made the day before dialysis and
blood drawn for creatinine estimation at the end of the collec-
tion period, there was a systematic tendency to underestimate
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Group data are given as means [± SEMI with ranges. The
significance of differences between serum Al concentrations in
groups classified according to the amount of urine passed was
assessed by the Kruskal—Wallis test. The correlations between
serum Al concentration and Al exposure, urine volume, and Al
clearance, were derived after log transformation by linear
regression and all possible subsets multiple linear regression
1181. A two-tailed significance value of P < 0.05 was regarded as
significant.
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Relationship between aluminum exposure and serum
aluminum concentration
The mean serum Al concentration was 60.9 4.1 pg/liter (5
to 290 jsg/iiter); total oral elemental Al intake, 1056.2 107.0 g
(0 to 6374g); monthly soft water Al concentration, 8.4 0.8
j.g/liter (1 to 39.8 j.g/liter); cumulative soft water Al, 991 124
mg (4—6186 mg); total dialysis hours, 4607.2 432.8 hr (132 to
18770 hr). Serum Al correlated with total oral Al intake (r =0.53,
P < 0.001), cumulative soft water Al exposure (r = 0.40, P <
0.001) and the total number of dialysis hours (r =0.37, P < 0.001).
Relationship between serum aluminum concentration and
urine flow
The mean urine volume was 369.8 51.0 mi/day (0 to 2060
mi/day). There appeared to be a curvilinear relationship be-
tween urine volume and serum Al, and comparisons between
subgroups of patient with differing ranges of urine flow rate
showed significant differences between their serum Al concen-
trations (Table 1). The influence of urine volume was confirmed
by linear regression analysis of log transformed data which
showed serum Al to be inversely related to urine flow (r =
— 0.52, P < 0.001). This relationship was also seen in a separate
analysis of the 62 patients who passed more than 10 ml urine per
day (r = —0.58, P < 0.001), (Fig. 1). No correlation was found
between urine volume and oral Al intake (r =
—0.16, P > 0.1)
among those patients whose daily urine output exceeded 10 ml.
Multivariate analysis
To examine the separate contributions made by urine vol-
ume, oral Al intake, cumulative soft water Al, and total HD
hours to serum Al concentration, and the potential effect of
duration of treatment on the relationship between serum Al and
urine volume, all possible subsets multiple linear regression
analysis was performed. This procedure was confined to the 62
patients in whom urine flow was more than 10 mi/day. The
multiple correlation coefficient (r) was 0.70 and adjusted r2 was
0.45, (P < 0.001). The percentage contributions to r2 were:
urine volume 57%; total oral Al 36%; total HD hours 7%; the
additional contributions from cumulative soft water Al or from
mean soft water Al were negligible.
Relationship between serum aluminum levels, creatinine, and
aluminum clearance
Creatinine clearance, urinary Al, and Al clearance were
measured in 26 randomly selected patients whose urine output
exceeded 10 mI/day, The mean creatinine clearance was 1.26
0.21 ml/min (0.05 to 4.15 mI/mm), urine Al was 15.4 2.7
pg/day (1.9 to 52.8 jsg/day) and Al clearance was 0.38 0.09
ml/min (0.02 to 1.96 mI/mm). Serum Al (mean 44.4 5.6
jsg/liter, range 5 to 105 Lg/liter) was inversely correlated with
creatinine clearance (r =
—0.58, P — 0.002), (Fig. 2), and Al
clearance (r —
—0.69, P < 0.001), (Fig. 3). In addition there was
a good correlation between creatinine and Al clearances, (r =
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Table 1. Relationship between serum Al and urine flow
Urine volume Mean serum Al Kruskal-
mi/day N jig/liter [±5EMJ Wallis
— -
<10 44 76.8 75
10—250 24 68.6 6.6 P < 0 001250—500 12 62.6 9.1
>500 26 26.2 2.9
the true creatinine clearance. However the error would be
qualitatively the same in all patients.
Calculation of aluminum exposure. The cumulative Al expo-
sure due to hemodialysis itself was calculated as the product of
the mean of the regular measurements of softened water Al
concentrations, the total number of hours dialyzed since the
start of dialysis, and the dialysate flow rate. Total oral Al
exposure was calculated from the product of daily intake and
number of days of treatment. Calculation of cumulative oral Al
intake was from the onset of dialysis dependency.
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Fig. 1. Relationship between urine flow (mi/day; loge scale) and serum
aluminum (Al) concentration (jig/liter; loge scale) in 62 hemodialysis
patients in whom urine flow was greater than 10 mI/day, (r = —0.58, P
<0.001).
Group data are given as means [± SEMI with ranges. The
significance of differences between serum Al concentrations ingroups classified according to the amount of urine passed was
assessed by the Kruskal—Wallis test. The correlations between
serum Al concentration and Al exposure, urine volume, and Alclearance, were derived after log transformation by linear
regression and all possible subsets multiple linear regression1181. A two-tailed significance value of P < 0.05 was regarded assignificant.Results
U.a)'aEcca)C',
Relationship between aluminum exposure and serumaluminum concentrationThe mean serum Al concentration was 60.94.1 pg/l ter (5to 290 jsg/iiter); total oral elemental Al intake, 1056.2107.0 g(0 to 6374g); monthly soft water Al concentration, 8.4.8j.g/liter (1 to 39.8 j.g/liter); cumulative soft water Al, 99124mg (4—6186 mg); total dialysis hours, 4607.2432.8 hr (132 to18770 hr). Serum Al correlated with total oral Al intake (r =0.5 ,P < 0.001), cumulative soft water Al exposure (r =.40P <0.001) and the total number of dialysis hours (r =0.37,P < 0.0 1).
Relationship between serum aluminum concentration andurine flowThe mean urine volume was 369.851.0 mi/day (0 to 2060
mi/day). There appeared to be a curvilinear relationship be-tween urine volume and serum Al, and comparisons betweensubgroups of patient with differing ranges of urine flow rate
showed significant differences between their serum Al concen-trations (Table 1). The influence of urine volume was confirmedby linear regression analysis of log transformed data whichshowed serum Al to be inversely related to urine flow (r =— 0.52,P < 0.001). This relationship was also seen in a separate
analysis of the 62 patients who passed more than 10 ml urine perday ( =. 8,P < 0.001), (Fig. 1). No correlation was foundbetween urine volume and oral Al intake (r =—0.16,P > 0.1)among those patients whose daily urine output exceeded 10 ml.
Multivariate analysis
To examine the separate contributions made by urine vol-
ume, oral Al intake, cumulative soft water Al, and total HD
hours to serum Al concentration, and the potential effect of
duration of treatment on the relationship between serum Al and
urine volume, all possible subsets multiple linear regression
analysis was performed. This procedure was confined to the 62
patients in whom urine flow was more than 10 mi/day. The
multiple correlation coefficient (r) was 0.70 and adjusted r2 was
0.45, (P < 0.001). The percentage contributions to r2 were:
urine volume 57%; total oral Al 36%; total HD hours 7%; the
additional contributions from cumulative soft water Al or from
mean soft water Al were negligible.
Relationship between serum aluminum levels, creatinine, andalu inum clearance
Creatinine clearanc , urinary Al, and Al clearance were
measured in 26 randomly selected patients whose urine output
exceeded 10 mI/day, The mean creatinine clearance was 1.26
0.21 ml/min (0.05 to 4.15 I/mm), urine Al was 15.42.7
pg/day (1.9 to 52.8 jsg/day) and Al clearance was 0.380.09
ml/min (0.02 to 1.96 mI/mm). Serum Al (mean 44.45.6
jsg/liter, range 5 to 105 Lg/liter) was inversely correlated withcreatinin  clearance (r =—0.58,P —.002),(Fig. 2), and Alclear nce (r —— 9,P < 0.0 1), (Fig. 3). In addition there was
 good cor elation between creatinine and Al clearances, (r =
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the true creatinine clearance. However the error would bequalitatively the same in all patients.Calculation of aluminum exposure. The cumulative Al expo-
sure due to hemodialysis itself was calculated as the product ofthe mean of the regular measurements of softened water Alconcentrations, the total number of hours dialyzed since thestart of dialysis, and the dialysate flow rate. Total oral Al
exposure was calculated from the product of daily intake and
number of days of treatment. Calculation of cumulative oral Alintake was from the onset of dialysis dependency.
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aluminum (Al) concentration (jig/liter; loge scale) in 62 hemodialysis
patients in whom urine flow was greater than 10 mI/day, (r =—0.58,P<0. 01).
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intake or softened water between those patients whose urine
outputs were less than or greater than 500 mI/day.
Discussion
We have shown that residual renal function is an important
determinant of serum Al in hemodialyzed patients. We have
considered the possibility that the relationship is indirect, due
to reduction in the consumption of Al-containing phosphate
binders consequent on urinary phosphate excretion being greater
in those patients passing more urine. Although we did not
measure urinary phosphate excretion, there was no relationship
between urine volume and the consumption of phosphate
binders (urine volume vs. oral Al intake: r =
—0.16, P > 0.1).
Multivariate analysis indicated that serum Al concentration
was inversely related to urine flow. This relationship was
largely independent of any effect of total duration of dialysis on
serum Al or urine flow, although there was a tendency for
serum Al to increase and for urine flow to decrease with time.
The percentage contributions to r2 indicated that the urine
volume and oral Al intake had a far greater influence on serum
Al than did total hours on HD or soft water Al. Nevertheless
over half the variance of the serum Al concentrations remains
unexplained. While some of this may represent error variance,
there may be other factors making systematic contributions
which we have not studied. For example, serum Al concentra-
tion may not reflect total body Al accurately, and we could not
assess the effect of oral Al intake before the onset of dialysis
treatment or differences in dietary Al content. Other reports
have emphasized the importance of dialysate Al exposure
rather than oral Al intake in determining serum Al [4, 9].
However in our patients dialysate Al concentrations were much
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Fig. 4. Relationship between aluminum (Al) clearance (mi/mm) and
creatinine (Cr) clearance (mi/mm) in 26 hemodialysis patients in whom
urine flow was greater than 10 mI/day, (r = 0.75, P < 0.001).
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Fig. 2. Relationship between creatinine (Cr) clearance (mi/mm) and
serum aluminum (Al) concentration (pg/liter; loge scale) in 26 hemodi-
alysis patients in whom urine flow was greater than 10 mI/day, (r =
—0.58, P < 0.001).
150
55
C-
0)t
E
20
E
Co
E
U)
7
3
2
Fig. 3. Relationship between aluminum (Al) clearance (mi/mm) and
serum Al concentration (sag/liter; loge scale) in 26 hemodialysis patients
in whom urine flow was greater than 10 mi/day, (r = -0.69, P <0.001).
0.75, P < 0.001), (Fig. 4). No relationship was found between
serum Al and daily urine Al excretion (r = 0.09). There was no
significant difference in cumulative Al exposure from oral
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lower, with a consequent increase in the relative importance of
oral Al. Moreover multivariate analysis would minimize the
contribution of cumulative soft water Al in comparison to total
HD hours as these two factors were closely correlated. The
substitution, in the analysis, of cumulative soft water Al by
mean soft water Al did not alter the results.
Two additional measures of residual renal function (creati-
nine and aluminum clearances) correlated positively with each
other and inversely with serum Al. This lends support to the
view that residual renal function was a determinant of serum Al
concentration in these patients. It may seem surprising that the
very low Al excretion rates that we have documented (1.9 to
52.8 jxg/day) appear to exert a significant effect on serum Al,
and that, in spite of this apparent effect, there was no relation-
ship between serum Al and daily urinary Al excretion. This
seemingly paradoxical observation results from the cross—sec-
tional nature of the study. In any particular patient, a high Al
excretion rate may reflect either massive Al loading or high
renal Al clearance, or both. Conversely low Al excretion may
reflect very low or non-existent residual renal function or a
lesser degree of Al loading. Thus, because body Al burden and
current influx of Al differ widely between patients, daily Al
excretion rate would not be expected to correlate with serum Al
although, as we have shown, Al clearance and creatinine
clearance do. In addition, the low daily Al excretion in the urine
may reflect a very low combined fractional absorption of Al
from the intestine and dialysate. Other studies have found the
gastrointestinal absorption of Al to be much higher, up to
approximately 30% fractional absorption, than that suggested
by our results [10—12]. However in these studies Al supple-
ments were given to subjects between meals and the measure-
ments of normal serum Al concentration were much higher than
would be accepted now, indicating considerable differences in
methodology. In a more recent study in which Al was given
with meals, as would be the case when dialysis patients take
Al-containing phosphate binders, absorption was much lower
(less than 0.1%) [131.
In conclusion, we have shown that Al accumulation, and
potential toxicity, is more likely in those dialysis patients who
do not pass urine than in those who do and that quantitatively
important amounts of Al appear in the urine. It is possible that
this factor contributes to the tendencyof anuric dialysis patients
to develop more severe anemia, neuropathy and other compli-
cations of chronic renal failure than do those who continue to
pass urine [14, 15]. Because the major source of Al in these
patients was oral, rather than parenteral from dialysate, our
findings are likely to be relevant even after widespread adoption
of improved water purification by means of reverse osmosis and
deionisation. Consideration of the risk of Al toxicity faced by
patients on hemodialysis should take into account both the
estimated exposure to Al and its excretion in patients in whom
urine flow is maintained.
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